Association of Skeletal Muscle Wasting With Treatment With Sorafenib in Patients With Advanced Renal Cell Carcinoma: Results From a Placebo-Controlled Study
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Purpose: Effects of specific antineoplastic therapies on progression of cancer-associated wasting remain uncharacterized. We selected a targeted therapy, sorafenib, because of its reported association with weight loss. Patients and Methods: Patients with metastatic renal cell cancer (RCC) who were resistant to standard therapy (N = 80) received sorafenib 400 mg twice daily or placebo in a randomized, double-blinded clinical trial. Computed tomography image analysis, which has high precision and specificity for evaluation of specific muscles and adipose tissues, was used to define change in total skeletal muscle and adipose tissue. Results: At inclusion, 51% of patients were overweight or obese (ie, body mass index [BMI] > 25 kg/m 2). Only 5% were underweight. Advanced muscle wasting (ie, sarcopenia) was present in 72% of patients with BMI less than 25 and in 34% of those with a BMI greater than 25. Patients received placebo for an average of 6 months and received sorafenib for 1 year. Patients in the placebo group had stable body weight during 6 months (0.8 kg ± 0.7 kg), with no significant alteration of muscle or fat. Patients who received sorafenib lost 2.1 kg ± 0.6 kg (P < .01) in 6 months and lost 4.2 kg ± 0.7 kg (P < .01) by 1 year. Sorafenib-treated patients lost skeletal muscle progressively at 6 months (decrease of 4.9%; P < .01) and 12 months (decrease of 8.0%; P < .01). Conclusion: Sarcopenia is prevalent in patients with metastatic RCC and is an occult condition in patients with normal or high BMI. Muscle loss is specifically exacerbated by sorafenib, consistent with the evidence for a role of kinases in regulating muscle mass. Muscle loss is a sorafenib adverse effect that may relate to asthenia, fatigue, and physical disability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Self-citationEpidemiology of Sarcopenia among the Elderly in New Mexico
Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R., Garry, P. J., & Lindeman, R. D. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009520 · Cited by 4,004
Prado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70153-0 · Cited by 3,238
Self-citationBodine, S. C., Stitt, T. N., Gonzalez, M., Kline, W. O., Stover, G. L., Bauerlein, R., Zlotchenko, E., Scrimgeour, A., Lawrence, J. C., Glass, D. J., et al. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1014 · Cited by 2,752
Mourtzakis, M., Prado, C. M. M., Lieffers, J. R., Reiman, T., McCargar, L. J., & Baracos, V. E. (2008) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h08-075 · Cited by 2,224
Self-citationShen, W., Punyanitya, M., Wang, Z., Gallagher, D., St.-Onge, M.-P., Albu, J., Heymsfield, S. B., & Heshka, S. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00744.2004 · Cited by 1,692
Mitsiopoulos, N., Baumgartner, R. N., Heymsfield, S. B., Lyons, W., Gallagher, D., & Ross, R. (1998) · Journal of Applied Physiology · doi:10.1152/jappl.1998.85.1.115 · Cited by 1,522
Prado, C. M. M., Baracos, V. E., McCargar, L. J., Reiman, T., Mourtzakis, M., Tonkin, K., Mackey, J. R., Koski, S., Pituskin, E., & Sawyer, M. B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2242 · Cited by 1,104
Self-citationChanges in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697
Body Composition as an Independent Determinant of 5-Fluorouracil–Based Chemotherapy Toxicity
Prado, C. M. M., Baracos, V. E., McCargar, L. J., Mourtzakis, M., Mulder, K. E., Reiman, T., Butts, C. A., Scarfe, A. G., & Sawyer, M. B. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3067 · Cited by 619
Self-citation
Cited by
ESPEN guidelines on nutrition in cancer patients
Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., Fearon, K., Hütterer, E., Isenring, E., Kaasa, S., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.07.015 · Cited by 3,114
Self-citationBaracos, V. E., Martin, L., Korc, M., Guttridge, D. C., & Fearon, K. C. H. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.105 · Cited by 1,738
Self-citationESPEN practical guideline: Clinical Nutrition in cancer
Muscaritoli, M., Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., Hütterer, E., Isenring, E., Kaasa, S., et al. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.02.005 · Cited by 1,702
“Cancer patients, in general, report low levels of physical activity and both inactivity and cancer treatment [44,45] have serious adverse effects on muscle mass [46].”
BackgroundSelf-citationESPEN practical guideline: Clinical nutrition in surgery
Weimann, A., Braga, M., Carli, F., Higashiguchi, T., Hübner, M., Klek, S., Laviano, A., Ljungqvist, O., Lobo, D. N., Martindale, R. G., et al. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.03.031 · Cited by 1,173
Understanding the mechanisms and treatment options in cancer cachexia
Fearon, K., Arends, J., & Baracos, V. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.209 · Cited by 940
Self-citationImpact of Sarcopenia on Outcomes Following Resection of Pancreatic Adenocarcinoma
Peng, P., Hyder, O., Firoozmand, A., Kneuertz, P., Schulick, R. D., Huang, D., Makary, M., Hirose, K., Edil, B., Choti, M. A., et al. (2012) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-012-1923-5 · Cited by 546
Peng, P. D., van Vledder, M. G., Tsai, S., de Jong, M. C., Makary, M., Ng, J., Edil, B. H., Wolfgang, C. L., Schulick, R. D., Choti, M. A., et al. (2011) · HPB · doi:10.1111/j.1477-2574.2011.00301.x · Cited by 413
Marra, M., Sammarco, R., De Lorenzo, A., Iellamo, F., Siervo, M., Pietrobelli, A., Donini, L. M., Santarpia, L., Cataldi, M., Pasanisi, F., et al. (2019) · Contrast Media & Molecular Imaging · doi:10.1155/2019/3548284 · Cited by 401
“*e issue of drug distribution in muscles and its consequences in neoplastic patients with sarcopenia is further complicated by the evidence that some transduction therapy agents, such as sorafenib, may reduce muscle mass by a direct action [77].”
BackgroundUnderstanding, recognizing, and managing toxicities of targeted anticancer therapies
Dy, G. K., & Adjei, A. A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21184 · Cited by 331
“However, the hypovitaminosis D in association with hyperparathyroidism is thought to contribute to sorafenib-induced sarcopenia and may lead to osteomalacia.(129,130) Vitamin D supplementation can normalize the hypophosphatemia and PTH levels.”
BackgroundBozzetti, F. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx271 · Cited by 323
Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes
Kazemi-Bajestani, S. M. R., Mazurak, V. C., & Baracos, V. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.09.001 · Cited by 313
Self-citationAapro, M., Arends, J., Bozzetti, F., Fearon, K., Grunberg, S. M., Herrstedt, J., Hopkinson, J., Jacquelin-Ravel, N., Jatoi, A., Kaasa, S., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu085 · Cited by 308
Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact
Prado, C. M., Cushen, S. J., Orsso, C. E., & Ryan, A. M. (2016) · Proceedings of the Nutrition Society · doi:10.1017/s0029665115004279 · Cited by 300
Fugazzola, L., Elisei, R., Fuhrer, D., Jarzab, B., Leboulleux, S., Newbold, K., & Smit, J. (2019) · European Thyroid Journal · doi:10.1159/000502229 · Cited by 285
Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma
Joglekar, S., Asghar, A., Mott, S. L., Johnson, B. E., Button, A. M., Clark, E., & Mezhir, J. J. (2015) · Journal of Surgical Oncology · doi:10.1002/jso.23862 · Cited by 275
Cancer-induced muscle wasting: latest findings in prevention and treatment
Aversa, Z., Costelli, P., & Muscaritoli, M. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017698643 · Cited by 215
Daly, L. E., Ní Bhuachalla, É. B., Power, D. G., Cushen, S. J., James, K., & Ryan, A. M. (2018) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12267 · Cited by 204
“Muscle loss may also be as a consequence of some cancer directed therapies.(47)”
BackgroundThe evaluation of body composition: A useful tool for clinical practice
Thibault, R., & Pichard, C. (2012) · Annals of Nutrition and Metabolism · doi:10.1159/000334879 · Cited by 193
Crawford, J., Prado, C. M. M., Johnston, M. A., Gralla, R. J., Taylor, R. P., Hancock, M. L., & Dalton, J. T. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0522-0 · Cited by 178
Solheim, T. S., Laird, B. J. A., Balstad, T. R., Bye, A., Stene, G., Baracos, V., Strasser, F., Griffiths, G., Maddocks, M., Fallon, M., et al. (2018) · BMJ Supportive & Palliative Care · doi:10.1136/bmjspcare-2017-001440 · Cited by 178
Self-citationPrognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer
Kimura, M., Naito, T., Kenmotsu, H., Taira, T., Wakuda, K., Oyakawa, T., Hisamatsu, Y., Tokito, T., Imai, H., Akamatsu, H., et al. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-014-2534-3 · Cited by 175
“In addition, muscle wasting can be induced by anticancer treatments [8, 11, 12].”
BackgroundSorafenib: a clinical and pharmacologic review
Iyer, R., Fetterly, G., Lugade, A., & Thanavala, Y. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.496453 · Cited by 169
“Muscle loss is a sorafenib adverse effect that may relate to asthenia, fatigue and physical disability and should be evaluated more closely, especially in HCC patients who have muscle wasting due to liver failure, hypogonadism and hypoalbuminemia from their underlying cirrhosis, in addition to having cancer [44].”
BackgroundSheean, P., Gonzalez, M. C., Prado, C. M., McKeever, L., Hall, A. M., & Braunschweig, C. A. (2020) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.1669 · Cited by 164
Drug–Nutrient Interactions: A Broad View with Implications for Practice
Boullata, J. I., & Hudson, L. M. (2012) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jada.2011.09.002 · Cited by 138
The advantages and limitations of cross-sectional body composition analysis
MacDonald, A. J., Greig, C. A., & Baracos, V. (2011) · Current Opinion in Supportive & Palliative Care · doi:10.1097/spc.0b013e32834c49eb · Cited by 101
Self-citation
Metadata
- Authors
- Antoun, S., Birdsell, L., Sawyer, M. B., Venner, P., Escudier, B., & Baracos, V. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-02-20
- Volume
- 28
- Issue
- 6
- Pages
- 1054-1060
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2158151049
- Cited by
- 283
- References
- 27
- FWCI
- 9.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.